565 related articles for article (PubMed ID: 28056114)
21. Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenström macroglobulinemia.
Wang Y; Gali VL; Xu-Monette ZY; Sano D; Thomas SK; Weber DM; Zhu F; Fang X; Deng M; Zhang M; Hagemeister FB; Li Y; Orlowski RZ; Lee HC; Young KH
Neoplasia; 2021 Apr; 23(4):361-374. PubMed ID: 33735664
[TBL] [Abstract][Full Text] [Related]
22. Immunoglobulin M (IgM) multiple myeloma versus Waldenström macroglobulinemia: diagnostic challenges and therapeutic options: two case reports.
Elba S; Castellino A; Soriasio R; Castellino C; Bonferroni M; Mattei D; Strola G; Drandi D; Mordini N; Foglietta M; Rapezzi D; Celeghini I; Grasso M; Giordano F; Fraternali Orcioni G; Massaia M
J Med Case Rep; 2020 Jun; 14(1):75. PubMed ID: 32564775
[TBL] [Abstract][Full Text] [Related]
23. Bortezomib as a treatment option in patients with Waldenström macroglobulinemia.
Dimopoulos MA; Chen C; Kastritis E; Gavriatopoulou M; Treon SP
Clin Lymphoma Myeloma Leuk; 2010 Apr; 10(2):110-7. PubMed ID: 20371443
[TBL] [Abstract][Full Text] [Related]
24. [Therapy of Waldenström´s macroglobulinaemia in the year 2014].
Adam Z; Krejčí M; Pour L; Ševčíková E
Vnitr Lek; 2014 Feb; 60(2):139-57. PubMed ID: 24754419
[TBL] [Abstract][Full Text] [Related]
25. SOHO State of the Art Updates and Next Questions: Targeted therapies and emerging novel treatment approaches for Waldenström Macroglobulinemia.
Sermer D; Sarosiek S; Branagan AR; Treon SP; Castillo JJ
Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):547-556. PubMed ID: 35339405
[TBL] [Abstract][Full Text] [Related]
26. Waldenström macroglobulinemia: 2012 update on diagnosis, risk stratification, and management.
Gertz MA
Am J Hematol; 2012 May; 87(5):503-10. PubMed ID: 22508368
[TBL] [Abstract][Full Text] [Related]
27. Current therapy guidelines for Waldenstrom's macroglobulinaemia.
Kastritis E; Dimopoulos MA
Best Pract Res Clin Haematol; 2016 Jun; 29(2):194-205. PubMed ID: 27825466
[TBL] [Abstract][Full Text] [Related]
28. Current options to manage Waldenström's macroglobulinemia.
Benevolo G; Nicolosi M; Santambrogio E; Vitolo U
Expert Rev Hematol; 2017 Jul; 10(7):637-647. PubMed ID: 28592170
[TBL] [Abstract][Full Text] [Related]
29. Waldenström macroglobulinemia: 2013 update on diagnosis, risk stratification, and management.
Gertz MA
Am J Hematol; 2013 Aug; 88(8):703-11. PubMed ID: 23784973
[TBL] [Abstract][Full Text] [Related]
30. An unusual case of cutaneous Waldenström macroglobulinemia with the MYD88 L265P mutation.
Minzenmayer AN; Miranda RN; Powell PR; Parekh PK
J Cutan Pathol; 2020 Sep; 47(9):850-853. PubMed ID: 32335928
[TBL] [Abstract][Full Text] [Related]
31. Current approach to Waldenström Macroglobulinemia.
Ravi G; Kapoor P
Cancer Treat Res Commun; 2022; 31():100527. PubMed ID: 35149375
[TBL] [Abstract][Full Text] [Related]
32. Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
Gertz MA; Anagnostopoulos A; Anderson K; Branagan AR; Coleman M; Frankel SR; Giralt S; Levine T; Munshi N; Pestronk A; Rajkumar V; Treon SP
Semin Oncol; 2003 Apr; 30(2):121-6. PubMed ID: 12720120
[TBL] [Abstract][Full Text] [Related]
33. A Canadian Perspective on the Treatment of Waldenström Macroglobulinemia.
Kaedbey R; Forward N; Sehn LH; Shafey M; Doucette S; Chen CI
Curr Oncol; 2022 Sep; 29(10):7122-7139. PubMed ID: 36290837
[TBL] [Abstract][Full Text] [Related]
34. Phase I/II trial of everolimus in combination with bortezomib and rituximab (RVR) in relapsed/refractory Waldenstrom macroglobulinemia.
Ghobrial IM; Redd R; Armand P; Banwait R; Boswell E; Chuma S; Huynh D; Sacco A; Roccaro AM; Perilla-Glen A; Noonan K; MacNabb M; Leblebjian H; Warren D; Henrick P; Castillo JJ; Richardson PG; Matous J; Weller E; Treon SP
Leukemia; 2015 Dec; 29(12):2338-46. PubMed ID: 26139427
[TBL] [Abstract][Full Text] [Related]
35. Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemia.
Tedeschi A; Picardi P; Ferrero S; Benevolo G; Margiotta Casaluci G; Varettoni M; Baratè C; Motta M; Gini G; Goldaniga MC; Visco C; Zaja F; Belsito Petrizi V; Ravelli E; Gentile M; Urbano MA; Franceschetti S; Ghione P; Orsucci L; Frustaci AM; Gaidano G; Vitolo U; Morra E
Leuk Lymphoma; 2015; 56(9):2637-42. PubMed ID: 25651423
[TBL] [Abstract][Full Text] [Related]
36. Report of consensus panel 1 from the 11
Buske C; Castillo JJ; Abeykoon JP; Advani R; Arulogun SO; Branagan AR; Cao X; D'Sa S; Hou J; Kapoor P; Kastritis E; Kersten MJ; LeBlond V; Leiba M; Matous JV; Paludo J; Qiu L; Tam CS; Tedeschi A; Thomas SK; Tohidi-Esfahani I; Varettoni M; Vos JM; Garcia-Sanz R; San-Miguel J; Dimopoulos MA; Treon SP; Trotman J
Semin Hematol; 2023 Mar; 60(2):73-79. PubMed ID: 37099027
[TBL] [Abstract][Full Text] [Related]
37. What is new in the treatment of Waldenstrom macroglobulinemia?
Castillo JJ; Treon SP
Leukemia; 2019 Nov; 33(11):2555-2562. PubMed ID: 31591468
[TBL] [Abstract][Full Text] [Related]
38. Waldenström's macroglobulinemia - clinical symptoms and review of therapy yesterday, today and tomorrow.
Adam Z; Pour L; Zeman D; Krejčí M; Boichuk I; Krejčí M; Štork M; Sandecká V; Král Z
Klin Onkol; 2023; 36(3):177-191. PubMed ID: 37353346
[TBL] [Abstract][Full Text] [Related]
39. Waldenström macroglobulinemia.
Gertz MA
Hematology; 2012 Apr; 17 Suppl 1():S112-6. PubMed ID: 22507796
[TBL] [Abstract][Full Text] [Related]
40. Bortezomib in multiple myeloma and lymphoma: a systematic review and clinical practice guideline.
Reece D; Imrie K; Stevens A; Smith CA;
Curr Oncol; 2006 Oct; 13(5):160-72. PubMed ID: 22792013
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
